The Promising Role of Oncomarkers CA 19-9 and CA 125 in the Diagnosis of Progressive Pulmonary Fibrosis

Abstract

Purpose of the study to study the role of serum glycoproteins CA 19–9 and CA 125 as a potential non-invasive biomarker of progressive fibrosis in interstitial lung diseases.Materials and methods. The study included 77 patients with interstitial diseases. Based on the presence/absence of signs of progression over the previous 6 months, patients were divided into 2 groups. All patients underwent forced spirometry, body plethysmography, diffusion test, computed tomography of the chest, and a study of serum concentrations of CA 19-9 and CA 125.Results. In the group of patients with a progressive fibrotic phenotype of interstitial lung diseases (ILD), higher levels of CA 19-9 and CA 125 were detected. A correlation of the studied level of tumor markers with parameters of pulmonary function and the severity of interstitial changes in lung changes according to computed tomography of the chest was shown (Warrick test).Conclusion. The data obtained demonstrate the capabilities of non-invasive diagnosis of PF-ILD and require further research and prospective observation to assess the diagnostic and prognostic role of the studied biomarkers, as well as determine their place in clinical practice.